Superworth

Insulet price to free cash flow PODD

Market value divided by free cash flow over the last twelve months, since 2023.

Today, Nov 2, 2026
36.3×
3-year median
72.7×
Against its 3-year history
17th
percentile: 0 is its lowest day, 100 its highest
3-year range
24.2× to 474×
Peer median
18.8×

Insulet's price to free cash flow is 36.3× as of Nov 2, 2026.

That is below its 3-year median of 72.7×, lower than on 83% of days in the last 3 years.

Over that time it ranged from 24.2× in May 2026 to 474× in Aug 2023.

The median for 10 medical instruments and supplies stocks of a similar size is 18.8×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far36.3×24.2×48.0×
202547.9×47.9×87.4×
202481.9×66.8×353×
2023374×267×474×

Against its peers

Companies in Medical - Instruments & Supplies nearest Insulet's size, closest first, today.

CompanyPrice to free cash flow
PODDInsulet36.3×
GMEDGlobus Medical14.1×
ALGNAlign Technology17.3×
COOCooper Companies17.2×
PENPenumbra58.6×
SOLVSolventumn/m
MSAMSA Safety20.3×
HAEHaemonetics18.8×
MMSIMerit Medical Systems24.8×
VNTVontier12.9×
BMIBadger Meter31.6×
Peer median18.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Insulet

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.